I believe that there are some on this board who are quite fond of TMSRX, T Rowe Price's
Multi Strategy Total Return Fund.
The fund receives 4 Stars From Morningstar, and - as referenced in link above -
uses a highly flexible investment approach in an effort to provide strong risk-adjusted returns. This fund - classified by Morningstar as a "Multialternative" fund - bears a
net expense ratio of 1.22%.
One can, however, construct something similar using T Rowe Price Funds, that would seem to also deserve consideration. This roll-your-own ("RYO") alternative alternative, so to speak, is not as expensive as TMSRX, and this apparent cost-saving may be the source of the RYO advantage.
Below is a link to the RYO at PortfolioVisualizer. The link compares TMSRX to a combination of two TRP funds:
1. T. Rowe Price
QM U.S. Bond Index Fund, with an ER of 25 bps; and
2. T. Rowe Price
Global Allocation Fund, with an ER of 95 bps.
PV1: Portfolio Visualizer Regressionhttps://tinyurl.com/tmsrx-alt-fitIf we combine these two funds using a 70/30 allocation that was suggested by the PV tool, then you get a two-fund combo, with a 46 bps weighted average expense ratio - 76 bps below the ER of TMSRX. More details are at the link below.
PV2: Portfolio Visualizer RYO Backtesthttps://tinyurl.com/tmsrx-synth-ryoThe synthetic RYO alternative possessed better Sharpe and Sortino ratios than TMSRX, better 'Worst Year', better 'Best Year', a lower standard deviation, etc. The compound average growth rate of the RYO exceeds that of TMSRX by 61 bps, just as the regression alpha of the RYO exceeded that of TMSRX by about 75 bps - see PV1.
By construction, the RYO alternative uses funds drawn from the T Rowe stable. If you're looking for the
special insight or advantage conferred by T Rowe Price's deep bench, then have at it.
I just wonder if you need to spend 122 bps a year for the privilege.
PS:
[1] 03-14-21 Thank you to Crash, et al., for their
post on RPGAX, which got me thinking about RPGAX and TMSRX.
[2] 03-16-21 FWIW,
TMSRX 'Asset Class' correlations, via PV.
[3] 03-16-21 And here is link to synthetic versions, constructed from a
handful of asset classes.
Comments
Umm ... Why are we doing a performance comparison for a fund barely 3 years old? I’d argue anything can happen over such a short period. As far as fees go, TMSRX engages in short sales of securities - a CYA tactic against steep equity losses. Funds that engage in shorting typically have higher costs due to borrowing cash to cover the shorts. At one time they were able to hide those costs inside a fund’s operating costs, but SEC regs a couple decades back required those to be shown in the ER - hence an elevated ER. As a relatively new fund, fees for TMSRX are probably higher now than what TRP will eventually establish as assets grow. (Getting to the front of the line sometimes costs extra.)
PBDIX* is, of course, a plain vanilla intermediate term investment grade bond index fund with relatively low fees. I owned it during 2020, but unloaded it early this year in favor of shorter duration funds. RPGAX is a global balanced fund with an added 10% hedge fund exposure. Its managers do apply some interesting defensive tactics using derivatives. I wouldn’t be surprised if they’re shorting something (likely a bond or equity index), but would expect that to be in substantially lesser proportion and less frequently applied than what TMSRX does.
“Fond of TMSRX”? - All things are relative. I’d put it differently. TMSRX is a refuge for those “not fond” of either equity or fixed income valuations today. It’s a defensive fund.
Disclosure: TMSRX represents 16-17% of portfolio.
* Fund ticker symbol (PBDIX) was initially incorrect. Have corrected.
-
Here’s a tool that lets you run side by side comparisons of up to 5 funds for periods of 1, 3 or 5 years. It allows you to play around with time period covered as well as looking at both a linear graph and a side by side table comparison. Clicking “performance” pulls up a linear graph. One of the better tools I’ve come across and what I used in comparing the funds under discussion.
https://markets.ft.com/data/funds/us/compare